Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0286)
Name
Isoliquiritin
Synonyms
Isoliquiritin; 5041-81-6; Isoliquiritoside; 7014-39-3; UNII-2Y348H1V4W; CHEBI:80839; 2Y348H1V4W; (E)-1-(2,4-dihydroxyphenyl)-3-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]prop-2-en-1-one; 4-beta-D-glucopyranosyloxy-2',4'-dihydroxy-trans-chalcone; 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(4-(beta-D-glucopyranosyloxy)phenyl)-, (2E)-; 4-[(1E)-3-(2,4-dihydroxyphenyl)-3-oxoprop-1-en-1-yl]phenyl beta-D-glucopyranoside; 4-((1E)-3-(2,4-dihydroxyphenyl)-3-oxoprop-1-en-1-yl)phenyl beta-D-glucopyranoside; 2-PROPEN-1-ONE, 1-(2,4-DIHYDROXYPHENYL)-3-(4-(.BETA.-D-GLUCOPYRANOSYLOXY)PHENYL)-, (2E)-; 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-[4-(.beta.-D-glucopyranosyloxy)phenyl]-, (2E)-; SCHEMBL676338; CHEMBL599763; MEGxp0_001945; YNWXJFQOCHMPCK-LXGDFETPSA-N; DTXSID901317746; HY-N0765; BDBM50362885; LMPK12120021; MFCD00272145; s9293; AKOS015897131; CCG-268868; AC-34973; AS-56442; CS-0009792; I1144; C16978; A918375; Q-100563; Q27151336; (E)-1-(2,4-Dihydroxyphenyl)-3-(4-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)phenyl)prop-2-en-1-one; (E)-1-(2,4-dihydroxyphenyl)-3-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxyphenyl]prop-2-en-1-one

    Click to Show/Hide
Structure
Formula
C21H22O9
IUPAC Name
(E)-1-(2,4-dihydroxyphenyl)-3-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]prop-2-en-1-one
Canonical SMILES
C1=CC(=CC=C1C=CC(=O)C2=C(C=C(C=C2)O)O)OC3C(C(C(C(O3)CO)O)O)O
InChI
InChI=1S/C21H22O9/c22-10-17-18(26)19(27)20(28)21(30-17)29-13-5-1-11(2-6-13)3-8-15(24)14-7-4-12(23)9-16(14)25/h1-9,17-23,25-28H,10H2/b8-3+/t17-,18-,19+,20-,21-/m1/s1
InChIKey
YNWXJFQOCHMPCK-LXGDFETPSA-N
PubChem CID
5318591
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Breast cancer ICD-11: 2C60
 Disease Info 
Responsed Regulator Transcription factor p65 (RELA) Suppressor
 Regulator Info 
Pathway Response Ferroptosis hsa04216
Apoptosis hsa04210
Gluconeogenesis hsa00010
NF-kappa B signaling pathway hsa04064
Cell Process Cell ferroptosis
Cell apoptosis
Cell proliferation
In Vitro Model MDA-MB-231 cells Breast adenocarcinoma Homo sapiens CVCL_0062
MCF-7 cells Breast carcinoma Homo sapiens CVCL_0031
In Vivo Model
BALB/c nude mice (4 weeks old) were obtained from Charles river (Beijing, China). Mice were fed in a temperature-controlled SPF animal room with a 12-h cycle of light-dark. All animal experiments were ratified by the Animal Research Ethics Committee of Shenzhen Bao'an Traditional Chinese Medicine Hospital Group. 10 mice were subcutaneously inoculated with a total of 2106 of MDA-MB-231 cells and then divided into two groups at random, including the Model group and Iso group. Mice in the Iso group were intraperitoneally injected with 25?mg/kg/d Iso, while mice in the Model group were supplied with the same amount of phosphate buffer saline (PBS, Beyotime). Tumor volume was monitored every 4 d. Mice were sacrificed with the intraperitoneal introduction of sodium pentobarbital (100 mg/kg) after tumor cells treatment for 31 d, and the tumor samples were removed and weighed. Tumor volume was determined according to the formula: volume = 1/2 x length x width2.

    Click to Show/Hide
Response regulation Isoliquiritin notably counteracted the LPS-induced relative protein levels of p-p50/p50, p-p65/p65 (RELA), and IB, and the levels of ferroptosis, oxidative stress, glycolysis, and inflammation. Iso inhibited the NF-kB signaling to regulate ferroptosis and improved Dox-resistance in breast cancer.
References
Ref 1 Isoliquiritin modulates ferroptosis via NF-B signaling inhibition and alleviates doxorubicin resistance in breast cancer. Immunopharmacol Immunotoxicol. 2023 Dec;45(4):443-454. doi: 10.1080/08923973.2023.2165943. Epub 2023 Jan 17.